Focal HIFU Ablation of Prostate Cancer Using Advanced Ultrasound Guidance

使用先进超声引导进行前列腺癌局灶 HIFU 消融

• 批准号: 8231444
• 负责人: Ernest Joseph Feleppa
• 金额: $ 48.92万
• 依托单位: RIVERSIDE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-03 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8231444
• 关键词: 3-Dimensional; Ablation; Achievement; Address; Adverse effects; Biopsy; Brachytherapy; Cancerous; Classification; Clinical; Clinical Data; Cold Therapy; Computer software; Core Biopsy; Country; Cryosurgery; Data; Databases; Detection; Developed Countries; Development; Diagnostic; Dose; England; Excision; External Beam Radiation Therapy; Focused Ultrasound Therapy; Gland; Gold; Histocompatibility Testing; Histologic; Histology; Hospitals; Image; Image Guided Biopsy; Impotence; Investigation; Lesion; Location; London; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Malignant neoplasm of prostate; Marketing; Medical center; Methods; Modality; NIH Program Announcements; Nerve; Operative Surgical Procedures; Patients; Procedures; Prostate; Prostatic Diseases; Radiation; Radiation therapy; Rectal Fistula; Recurrence; Research; Research Institute; Salvage Therapy; Shapes; Spatial Distribution; Spectrum Analysis; System; Therapeutic; Time; Tissues; Ultrasonic Therapy; Ultrasonics; Ultrasonography; United States; United States National Institutes of Health; Universities; Urethral Obstruction; Urinary Incontinence; Validation; Virginia; base; cancer imaging; cancer therapy; college; cost; experience; high risk; imaging modality; improved; in vivo; instrument; men; novel strategies; prototype; public health relevance; quantum

DESCRIPTION (provided by applicant): Riverside Research Institute (RRI) and Focus Surgery, Inc. (FSI) propose an Academic-Industrial Partnership to develop and evaluate advanced ultrasonic means of guiding biopsies and treatment of prostate cancer, particularly treatment using focused ablative ultrasonic therapy. The proposed approach represents a very significant advancement in detection and treatment for this very common cancer of men in the United States and other developed countries worldwide. The proposed RRI-FSI Partnership specifically addresses NIH Program Announcement PAR-07-214, "Development and Validation of In-vivo Imaging Systems and Methods for Cancer Investigations." We seek to integrate advanced ultrasonic means of imaging prostate cancer that have been developed by RRI with a proven ultrasonic instrument that has been developed and manufactured by FSI for ablative treatment of prostate cancer. Conventional imaging methods cannot distinguish cancerous from non-cancerous prostate tissue, and consequently, all current biopsy and treatment methods essentially involve the entire gland. By emphasizing combined ultrasonic means of imaging cancer and treating it, we will overcome current imaging limitations, obviating the current need to ablate all tissue in the gland, and enabling treatment to be targeted to image cancerous tissue. This elegant integration of ultrasonic imaging and treatment modalities represents a novel approach to more-effectively treating only cancerous tissue in the prostate while reducing adverse side effects. By providing an effective means of delivering focal treatment, the proposed methods represent a quantum step forward in prostate-cancer management. The significance of these methods extends to biopsy guidance in general and to focal treatments of any type, including surgery, cryoablation, and radiation therapy. The proposed studies consist of three component efforts: 1) expanding our existing prostate-tissue data base and refining our tissue classification methods using transrectal 12-core biopsy histology gold standards; 2) evaluating targeting efficacy using transperineal template-guided saturation-biopsy histology gold standards; and 3) developing methods to identify viable cancer regions in radiation-treated patients who require salvage therapy. The proposed RRI-FSI Partnership will include internationally respected clinical collaborators who are experienced in the use of RRI's tissue-type imaging methods and FSI's ultrasonic ablation instrument. Our clinical collaborators are affiliated with the Virginia Mason Medical Center in Seattle, WA and the University College London Hospitals in London, England. PUBLIC HEALTH RELEVANCE: Riverside Research Institute and Focus Surgery, Inc. propose an Academic-Industrial Partnership to develop and evaluate advanced ultrasonic means of guiding prostate-cancer biopsies and treatment, particularly ablative ultrasonic therapy. The proposed approach represents a very significant advance in detection and therapy for this very common cancer of men in the United States and developed countries worldwide.

描述（由申请人提供）：河滨研究所（RRI）和Focus Surgery，Inc。（FSI）提出了一种学术工业合作伙伴关系，以开发和评估先进的超声波手段指导活检和治疗前列腺癌，尤其是使用聚焦的超声疗法治疗。拟议的方法代表了美国和全球其他发达国家这种非常普遍的男性癌症的检测和治疗方面的显着进步。拟议的RRI-FSI合作伙伴关系专门讨论了NIH计划公告PAR-07-214，“开发和验证体内成像系统和癌症调查方法”。我们试图整合由RRI开发的成像前列腺癌的高级超声波手段，并通过FSI开发和制造了一种经过验证的超声仪器，以消除前列腺癌的治疗。常规的成像方法不能将癌性与非癌性前列腺组织区分开，因此，所有当前的活检和治疗方法本质上都涉及整个腺体。通过强调将癌症成像和治疗的超声检查的组合手段，我们将克服当前的成像局限性，消除当前消融腺体中所有组织的需求，并使治疗能够针对癌组织形象。超声成像和治疗方式的这种优雅整合代表了一种新型的方法，可以在前列腺中仅处理癌组织，同时减少不良副作用。通过提供提供焦点治疗的有效手段，提出的方法代表了前列腺癌管理中向前迈出的量子一步。这些方法的重要性通常扩展到活检指导和任何类型的焦点治疗，包括手术，冷冻疗法和放射治疗。拟议的研究包括三个组成部分：1）扩大我们现有的前列腺组织数据库，并使用转直肠直直直骨活检组织学金标准来完善我们的组织分类方法； 2）评估使用经玻璃模板引导的饱和生物检查组织学黄金标准品评估靶向疗效； 3）开发方法来鉴定需要挽救疗法的辐射治疗患者中可行的癌症区域。拟议的RRI-FSI合作伙伴关系将包括具有国际尊敬的临床合作者，这些临床合作者在使用RRI的组织型成像方法和FSI的超声波消融工具方面经验丰富。我们的临床合作者与华盛顿州西雅图的弗吉尼亚梅森医疗中心和英国伦敦的伦敦大学医院隶属于弗吉尼亚梅森医学中心。 公共卫生相关性：Riverside Research Institute and Focus Surgery，Inc。提出了一种学术工业合作伙伴关系，以开发和评估指导前列腺癌活检和治疗的先进超声波手段，尤其是消融性超声疗法。拟议的方法代表了美国和全球发达国家这种非常常见的男性癌症的检测和治疗方面的重要进展。